NeuroThera Labs, a clinical-stage biotech unit of SciSparc Ltd., has filed a U.S. patent application covering a combination therapy pairing MDMA with N-acylethanolamines for treating post-traumatic stress disorder, anxiety and eating disorders.
The application, submitted to the United States Patent and Trademark Office, describes formulations that include palmitoylethanolamide alongside MDMA, addressing factors such as therapeutic potency, dosing requirements, side effects and the therapeutic window. The filing builds on a collaboration between NeuroThera and Clearmind Medicine Inc., which together have published 13 global patent applications in this area.
NeuroThera focuses on central nervous system disorders, while SciSparc’s broader pipeline includes drug programs based on THC and CBD for Tourette syndrome, Alzheimer’s disease, autism spectrum disorder and status epilepticus. SciSparc, listed on NASDAQ under the ticker SPRC, said the patent application was submitted as part of its strategy to expand its intellectual property portfolio in psychedelic-assisted therapies.
The filing follows the FDA’s finalization in July 2026 of guidance on psychedelic drug development, which defines MDMA as a psychedelic and outlines considerations for clinical trials, including design, conduct, data collection, subject safety and new drug application requirements. The regulator notes that psychedelics can pose challenges due to their psychoactive effects and impact on mood, cognition and perception.
Clearmind Medicine, traded on NASDAQ as CMND, and NeuroThera, listed on the TSX Venture Exchange under NTLX, did not immediately respond to requests for comment.
